{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:13:50Z","timestamp":1760955230016},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,12,8]],"date-time":"2010-12-08T00:00:00Z","timestamp":1291766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00280-010-1527-2","type":"journal-article","created":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T10:20:18Z","timestamp":1291717218000},"page":"45-50","source":"Crossref","is-referenced-by-count":14,"title":["The role of imatinib plasma level testing in gastrointestinal stromal tumor"],"prefix":"10.1007","volume":"67","author":[{"given":"Suzanne","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,8]]},"reference":[{"key":"1527_CR1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"C Blanke","year":"2008","unstructured":"Blanke C, Rankin C, Demetri G et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. JCO 26:626\u2013632","journal-title":"JCO"},{"key":"1527_CR2","doi-asserted-by":"crossref","unstructured":"Blanke C, Demetri G, Von Mehren M et al (2008) Long-term results from a randomized phase ii trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. JCO 25:620\u2013625","DOI":"10.1200\/JCO.2007.13.4403"},{"issue":"5","key":"1527_CR3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/hupa.2002.123545","volume":"33","author":"CD Fletcher","year":"2002","unstructured":"Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33(5):459\u2013465","journal-title":"Hum Pathol"},{"issue":"5350","key":"1527_CR4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577\u2013580","journal-title":"Science"},{"issue":"5","key":"1527_CR5","first-page":"1259","volume":"152","author":"LG Kindblom","year":"1998","unstructured":"Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152(5):1259\u20131269","journal-title":"Am J Pathol"},{"issue":"14","key":"1527_CR6","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","volume":"344","author":"H Joensuu","year":"2001","unstructured":"Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052\u20131056","journal-title":"N Engl J Med"},{"issue":"7","key":"1527_CR7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472\u2013480","journal-title":"N Engl J Med"},{"issue":"2","key":"1527_CR8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","volume":"23","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23(2):70\u201383","journal-title":"Semin Diagn Pathol"},{"key":"1527_CR9","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/annonc\/mdq047","volume":"21","author":"J Martin-Broto","year":"2010","unstructured":"Martin-Broto J, Gutierrez A, Garcia-Del-Muro X et al (2010) Prognostic time dependence of deletions affecting condons 557 and\/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish group for sarcoma research (GEIS) study. Ann Oncol 21:1552\u20131557","journal-title":"Ann Oncol"},{"issue":"6","key":"1527_CR10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/SLA.0b013e3181724f9d","volume":"247","author":"C Keun Park","year":"2008","unstructured":"Keun Park C, Lee EJ, Kim M et al (2008) Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg 247(6):1011\u20131018","journal-title":"Ann Surg"},{"issue":"23","key":"1527_CR11","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342\u20134349","journal-title":"J Clin Oncol"},{"issue":"18","key":"1527_CR12","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","volume":"22","author":"CL Corless","year":"2004","unstructured":"Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22(18):3813\u20133825","journal-title":"J Clin Oncol"},{"issue":"8","key":"1527_CR13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","volume":"42","author":"M Debiec-Rychter","year":"2006","unstructured":"Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) EORTC soft tissue and bone sarcoma group; The Italian sarcoma group; Australasian gastrointestinal trials group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42(8):1093\u20131103","journal-title":"Eur J Cancer"},{"issue":"5607","key":"1527_CR14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708\u2013710","journal-title":"Science"},{"key":"1527_CR15","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"M Heinrich","year":"2008","unstructured":"Heinrich M, Owzar K, Corless C et al (2008) Correlation of kinase genotype and clinical outcome in the north american intergroup phase iii trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: calgb 150105 study by cancer and leukemia group B and Southwest oncology group. JCO 26:5360\u20135367","journal-title":"JCO"},{"issue":"8","key":"1527_CR16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","volume":"42","author":"M Debiec-Rychter","year":"2006","unstructured":"Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42(8):1093\u20131103","journal-title":"Eur J Cancer"},{"issue":"7","key":"1527_CR17","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2009.24.2099","volume":"28","author":"Gastrointestinal Tumor Meta-analysis Group (metaGIST)","year":"2010","unstructured":"Gastrointestinal Tumor Meta-analysis Group (metaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: an analysis of 1,640 patients. JCO 28(7):1247\u20131253","journal-title":"JCO"},{"key":"1527_CR18","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","volume":"41","author":"JR Zalcberg","year":"2005","unstructured":"Zalcberg JR, Verweij J, Casali PG et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800\u00a0mg after progression on 400\u00a0mg. Eu J Cancer 41:1751\u20131757","journal-title":"Eu J Cancer"},{"issue":"1","key":"1527_CR19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","volume":"216","author":"B Liegl","year":"2008","unstructured":"Liegl B, Kepten I, Le C et al (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216(1):64\u201374","journal-title":"J Pathol"},{"key":"1527_CR20","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of imatinib therapy for newly diagnosed myeloid leukemia in chronic-phase shows sustained responses and high overall survival. New Engl J Med 355:2408\u20132417","journal-title":"New Engl J Med"},{"issue":"8","key":"1527_CR21","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic, molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496\u20133499","journal-title":"Blood"},{"issue":"8","key":"1527_CR22","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"R Larson","year":"2008","unstructured":"Larson R, Druker B, Guilhot F et al (2008) Imatinib pharmacokinetics, its correlation with response, safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022\u20134028","journal-title":"Blood"},{"key":"1527_CR23","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","volume":"12","author":"C Delbaldo","year":"2006","unstructured":"Delbaldo C, Chatelut E, Re M et al (2006) Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12:6073\u20136078","journal-title":"Clin Cancer Res"},{"key":"1527_CR24","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Wang Y, Wehrle E et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors. J Clin Oncol 27:3141\u20133147","journal-title":"J Clin Oncol"},{"key":"1527_CR25","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","volume":"98","author":"N Widmer","year":"2008","unstructured":"Widmer N, Decosterd L, Leyvraz S et al (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98:1633\u20131640","journal-title":"Br J Cancer"},{"key":"1527_CR26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-004-0876-0","volume":"55","author":"I Judson","year":"2005","unstructured":"Judson I, Ma P, Peng B et al (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumor: a retrospective population pharmacokinetic study over time. EORTC soft tissue and bone sarcoma group. Cancer Chemother Pharmacol 55:379\u2013386","journal-title":"Cancer Chemother Pharmacol"},{"key":"1527_CR27","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879\u2013894","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"1527_CR28","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"14","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J et al (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14(21):7102\u20137109","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1527_CR29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","volume":"80","author":"ER Gardner","year":"2006","unstructured":"Gardner ER, Burger H, van Schiek RH et al (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharm Ther 80(20):192\u2013201","journal-title":"Clin Pharm Ther"},{"key":"1527_CR30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myelogenous leukemia. N Eng J Med 344:1031\u20131037","journal-title":"N Eng J Med"},{"key":"1527_CR31","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2009.26.5785","volume":"28","author":"C Yoo","year":"2010","unstructured":"Yoo C, Ryu MH, Kang BW et al (2010) Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 28:1554\u20131559","journal-title":"J Clin Oncol"},{"issue":"24","key":"1527_CR32","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1200\/JCO.2005.11.601","volume":"23","author":"M Glabbeke Van","year":"2005","unstructured":"Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European organisation for research and treatment of cancer-Italian sarcoma group-Australasian gastrointestinal trials group study. J Clin Oncol 23(24):5795\u20135804","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1527-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1527-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1527-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T21:43:32Z","timestamp":1559857412000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1527-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,8]]},"references-count":32,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1527"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1527-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,8]]}}}